ATE518532T1 - Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz - Google Patents

Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz

Info

Publication number
ATE518532T1
ATE518532T1 AT10157595T AT10157595T ATE518532T1 AT E518532 T1 ATE518532 T1 AT E518532T1 AT 10157595 T AT10157595 T AT 10157595T AT 10157595 T AT10157595 T AT 10157595T AT E518532 T1 ATE518532 T1 AT E518532T1
Authority
AT
Austria
Prior art keywords
treatment
neuropathic pain
compounds
diabetic neuropathic
new use
Prior art date
Application number
AT10157595T
Other languages
English (en)
Inventor
Norma Selve
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8176866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE518532(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Application granted granted Critical
Publication of ATE518532T1 publication Critical patent/ATE518532T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT10157595T 2001-03-21 2002-03-19 Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz ATE518532T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01107026A EP1243263B1 (de) 2001-03-21 2001-03-21 Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Publications (1)

Publication Number Publication Date
ATE518532T1 true ATE518532T1 (de) 2011-08-15

Family

ID=8176866

Family Applications (3)

Application Number Title Priority Date Filing Date
AT01107026T ATE228358T1 (de) 2001-03-21 2001-03-21 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
AT02727436T ATE490766T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phatomschmerzen
AT10157595T ATE518532T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer peptidklasse von verbindungen zur behandlung von diabetischem neuropathischem schmerz

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT01107026T ATE228358T1 (de) 2001-03-21 2001-03-21 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phantomschmerzen
AT02727436T ATE490766T1 (de) 2001-03-21 2002-03-19 Neue verwendung einer klasse von peptidverbindungen zur behandlung von allodynie oder andere arten von chronischen oder phatomschmerzen

Country Status (26)

Country Link
US (3) US7875652B2 (de)
EP (3) EP1243263B1 (de)
JP (1) JP4154237B2 (de)
KR (1) KR100557852B1 (de)
CN (1) CN100522149C (de)
AT (3) ATE228358T1 (de)
AU (1) AU2002257680B2 (de)
BR (1) BR0208141A (de)
CA (1) CA2430470C (de)
CZ (1) CZ20032798A3 (de)
DE (2) DE60100055T2 (de)
DK (1) DK1243263T3 (de)
EA (1) EA007600B1 (de)
ES (3) ES2185606T3 (de)
HK (1) HK1048763B (de)
HU (1) HUP0303983A3 (de)
IL (3) IL155585A0 (de)
MX (1) MXPA03006438A (de)
NO (1) NO20033918L (de)
PL (1) PL368408A1 (de)
PT (1) PT1243263E (de)
SI (1) SI21169B (de)
SK (1) SK287714B6 (de)
UA (1) UA73854C2 (de)
WO (1) WO2002074297A1 (de)
ZA (1) ZA200303319B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243262B1 (de) 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
EP1537862A1 (de) * 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
WO2005053667A1 (en) * 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1629839A1 (de) * 2004-08-27 2006-03-01 Schwarz Pharma Ag Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
AR057643A1 (es) 2005-01-28 2007-12-12 Sanol Arznei Schwarz Gmbh Lacosamida para terapia adjunta
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20090253585A1 (en) * 2005-11-30 2009-10-08 Luda Diatchenko Identification of Genetic Polymorphic Variants Associated With Somatosensory Disorders and Methods of Using the Same
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
EP1920780A1 (de) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptidverbindungen zur Behandlung von Krankheiten mit erhöhter Erregbarkeit
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
WO2008070994A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
MD3310G2 (ro) * 2006-12-27 2008-02-29 Ион МЕРЕУЦЭ Metodă de tratament al durerilor fantome
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
WO2011037833A2 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
GB201200525D0 (en) * 2011-12-19 2012-02-29 Teva Branded Pharmaceutical Prod R & D Inc An inhalable medicament
US10034866B2 (en) 2014-06-19 2018-07-31 Teva Branded Pharmaceutical Products R&D, Inc. Inhalable medicament comprising tiotropium
KR20220147075A (ko) 2020-02-26 2022-11-02 에이지씨 가부시키가이샤 함불소 중합체, 막, 막의 제조 방법 및 유기 광전자 소자
FR3114739B1 (fr) * 2020-10-06 2022-08-26 Centre Nat Rech Scient Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (de) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
ES2133807T3 (es) 1994-10-05 1999-09-16 Darwin Discovery Ltd Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5651301A (en) * 1994-12-13 1997-07-29 Unipat Aktiengessellschaft Hydrostatic piston machines
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
EP0840612A1 (de) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibierung der nmda rezeptoraktivitaet durch pregnolonsulfatderivate
TW450807B (en) * 1995-09-15 2001-08-21 Pfizer Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614542A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6001876A (en) 1996-07-24 1999-12-14 Warner-Lambert Company Isobutylgaba and its derivatives for the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6038324A (en) * 1997-02-21 2000-03-14 Ambourn; Paul R. Automotive surround sound circuit background of the invention
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
JP2001521927A (ja) 1997-10-31 2001-11-13 ビーエーエスエフ アクチェンゲゼルシャフト アミド側鎖を有する新規のカルボン酸誘導体、その製造およびエンドセリン受容体アンタゴニストとしての使用
US6492553B1 (en) * 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6028102A (en) 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9812683D0 (en) * 1998-06-12 1998-08-12 Smithkline Beecham Plc Novel compounds
ES2295048T3 (es) 1999-09-03 2008-04-16 Actelion Pharmaceuticals Ltd. Bis-sulfonamidas.
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
WO2002013766A2 (en) 2000-08-17 2002-02-21 Teva Pharmaceutical Industries, Ltd. Valproic acid derivatives for the treatment of pain
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1695703B1 (de) * 2000-08-25 2010-08-11 Research Corporation Technologies, Inc. Aminosäure enthaltende Antikonvulsiva zur Behandlung von Zwangsstörungen
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ATE397584T1 (de) 2000-11-21 2008-06-15 Ucb Pharma Sa N-alkylierte gaba verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel
EP1243262B1 (de) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
EP1379523B1 (de) 2001-03-27 2005-07-27 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
WO2002088664A2 (en) 2001-04-26 2002-11-07 Bristol-Myers Squibb Company Control of compactability through crystallization
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US7485622B2 (en) 2002-11-18 2009-02-03 Bioprospecting Nb Inc. Paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US6991764B2 (en) * 2002-12-13 2006-01-31 Dade Behring Inc. Method for replacing used reaction cuvettes in an automatic analyzer depending upon next scheduled assay
CA2511385A1 (en) 2002-12-19 2004-07-22 Pharmacia Corporation Non-hygroscopic formulation comprising a hydroscopic drug
JP2006515326A (ja) 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 胃腸管障害を処置するためのナトリウムチャネルモジュレーターの使用
US20040209960A1 (en) 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
WO2004100871A2 (en) 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7307669B2 (en) * 2003-06-24 2007-12-11 Broadcom Corporation System, method, and apparatus for displaying streams with dynamically changing formats
US7320675B2 (en) 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (de) 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
WO2005053667A1 (en) 2003-12-02 2005-06-16 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1541138A1 (de) 2003-12-05 2005-06-15 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Status Epilepticus und ähnlicher Zustände
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1598428A1 (de) * 2004-05-18 2005-11-23 Georg Dewald Verfahren und Kits zum Nachweis von erblichen angioedema typ III
EP1604654A1 (de) 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006021412A2 (en) 2004-08-27 2006-03-02 Schwarz Pharma Ag Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (de) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 zur Co-Therapie der Schizophrenie
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (de) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US8735356B2 (en) * 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
JP4355003B2 (ja) * 2007-03-08 2009-10-28 本田技研工業株式会社 内燃機関の制御装置
US20100260716A1 (en) * 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
CN101841984A (zh) * 2009-03-19 2010-09-22 鸿富锦精密工业（深圳）有限公司 电子装置及其按键组件

Also Published As

Publication number Publication date
PL368408A1 (en) 2005-03-21
US7875652B2 (en) 2011-01-25
AU2002257680B2 (en) 2006-12-14
NO20033918D0 (no) 2003-09-04
ZA200303319B (en) 2003-07-08
SI21169B (sl) 2011-06-30
HUP0303983A2 (hu) 2004-04-28
HK1048763B (en) 2003-08-01
EA200300933A1 (ru) 2004-04-29
ES2185606T3 (es) 2003-05-01
JP2004524337A (ja) 2004-08-12
HUP0303983A3 (en) 2012-01-30
MXPA03006438A (es) 2004-05-24
CN100522149C (zh) 2009-08-05
EP1383487A1 (de) 2004-01-28
DK1243263T3 (da) 2003-03-17
NO20033918L (no) 2003-09-04
CA2430470A1 (en) 2002-09-26
US20040220077A1 (en) 2004-11-04
US20100099770A1 (en) 2010-04-22
ES2368317T3 (es) 2011-11-16
EP1383487B1 (de) 2010-12-08
EP1243263B1 (de) 2002-11-27
US20110082211A1 (en) 2011-04-07
CZ20032798A3 (cs) 2007-06-20
JP4154237B2 (ja) 2008-09-24
IL155585A0 (en) 2003-11-23
IL202688A0 (en) 2010-06-30
UA73854C2 (en) 2005-09-15
WO2002074297A1 (en) 2002-09-26
ATE228358T1 (de) 2002-12-15
IL155585A (en) 2010-12-30
KR100557852B1 (ko) 2006-03-10
ES2354417T3 (es) 2011-03-14
BR0208141A (pt) 2004-03-02
DE60100055T2 (de) 2003-07-24
CA2430470C (en) 2008-11-04
SI21169A (sl) 2003-10-31
EP2201943B1 (de) 2011-08-03
PT1243263E (pt) 2003-03-31
EP1243263A1 (de) 2002-09-25
HK1048763A1 (en) 2003-04-17
DE60238524D1 (de) 2011-01-20
DE60100055D1 (de) 2003-01-09
SK12902003A3 (sk) 2004-06-08
SK287714B6 (en) 2011-07-06
EP2201943A1 (de) 2010-06-30
KR20030076604A (ko) 2003-09-26
CN1498104A (zh) 2004-05-19
EA007600B1 (ru) 2006-12-29
ATE490766T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
DE60100055D1 (de) Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE60115019D1 (de) Reaktionssysteme zur herstellung von n-(phosphonomethyl)glyzin verbindungen
DE60223058D1 (de) Zusammensetzungen und verfahren zur behandlung von diabetes
DE50212243D1 (de) Prozess zur herstellung von aryl-aryl gekoppelten verbindungen
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
ATE455092T1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
ATE240107T1 (de) Neue verbesserte formulierung zur behandlung der osteoporose
DE60044884D1 (de) Verfahren zur Herstellung einer polymorphen Form von Atorvastatin calcium
ATE331512T1 (de) Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
ATE389411T1 (de) Strontium verbindung zur behandlung von sub- dermalem weichteilschmerz
DE10197144T1 (de) Verfahren zur Herstellung von Nitrilverbindungen aus ethylenisch ungesättigten Verbindungen
ATE452655T1 (de) Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung
DE60233433D1 (de) PHARMAZEUTISCHE ZUBEREITUNG enthaltend ein Catechin, Ascorbinsäure, Prolin und Lysin ZUR BEHANDLUNG VON NEOPLASTISCHEN KRANKHEITEN
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE60216457D1 (de) Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60107888D1 (de) Beta-Interferon zur Behandlung von Immunerkrankungen
ATE291921T1 (de) Verwendung von bisphosphonaten zur behandlung von osteogenese imperfecta
ATE506947T1 (de) Kondensierte thiophene verbindungen und deren verwendung zur behandlung von chronischen schmerzen
DE50212649D1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties